Astrazeneca's breast cancer drug fails late-stage trial
11/09/2026 21:26
Astrazeneca's breast cancer drug fails late-stage trial Sept 11 (Reuters) - AstraZeneca AZN.L said on Friday its breast cancer drug failed to meet the main goal of improving progression-free survival during a late-stage trial.
(Reporting by Christy Santhosh in Bengaluru; Editing by Tasim Zahid)
Recent news on Pfizer
See all newsBrief: Enanta Pharmaceuticals In Patent Infringement Action Against Pfizer
Brief: Edison Scientific Announces Agreement With Pfizer To Accelerate Research And Development
Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge (updated)
Corrected: Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge
Brief: Pfizer’S ELREXFIO Outperforms Standard Regimens And Meets Primary Endpoint In Phase 3 Study In Relapsed Or Refractory Multiple Myeloma